TABLE 2.

Summary of treatment-emergent adverse events.

	Single dose			Multiple-dose	Total
	1.5 mg (N = 12)	2.5 mg a (N = 12)	5 mg (N = 12)	2.5 mg (N = 12)	N = 49
Number of subjects (percent)
Any AEs	2 (16.7)	7 (58.3)	8 (66.7)	8 (61.5)	25 (51.0)
Dizziness	0 (0)	0 (0)	4 (33.3)	0 (0)	4 (8.2)
hyperuricemia	0 (0)	1 (8.3)	2 (16.7)	0 (0)	3 (6.1)
Upper respiratory tract infection	0 (0)	1 (8.3)	0 (0)	2 (15.4)	3 (6.1)
Myalgia	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (2.0)
Nasal obstruction	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (2.0)
Sinus tachycardia	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (2.0)
Ocular hypertension	0 (0)	1 (8.3)	0 (0)	0 (0)	1 (2.0)
DBP decreased	0 (0)	0 (0)	1 (8.3)	2 (15.4)	3 (6.1)
ECG PR shortened	0 (0)	1 (8.3)	0 (0)	0 (0)	1 (2.0)
ECG T wave abnormal	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (2.0)
Heart rate decreased	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (2.0)
Heart rate increased	1 (8.3)	1 (8.3)	0 (0)	0 (0)	2 (4.1)
Blood bilirubin increased	1 (8.3)	0 (0)	0 (0)	0 (0)	1 (2.0)
Blood TG increased	0 (0)	0 (0)	2 (16.7)	1 (7.7)	3 (6.1)
CRE increased	0 (0)	2 (16.7)	0 (0)	0 (0)	2 (4.1)
ALT increased	0 (0)	1 (8.3)	0 (0)	0 (0)	1 (2.0)
RBC urine positive	0 (0)	1 (8.3)	2 (16.7)	0 (0)	3 (6.1)
WBC urine positive	0 (0)	1 (8.3)	1 (8.3)	0 (0)	2 (4.1)
MC count increased	0 (0)	0 (0)	0 (0)	1 (7.7)	1 (2.0)
Urinary sediment present	0 (0)	1 (8.3)	0 (0)	0 (0)	1 (2.0)
Protein urine present	0 (0)	0 (0)	1 (8.3)	0 (0)	1 (2.0)

DBP: diastolic blood pressure; ECG: electrocardiogram; TG: triglycerides; CRE: serum creatinine; ALT: alanine aminotransferase; RBC: red blood cells; WBC: white blood cells; MC: mononuclear cell.

^a AEs, were counted for both fasted and fed phase after the single dose administration of dimdazenil.